机构:[1]Beijing Anzhen Hospital, Capital Medical University, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Collaborative Innovation Center for Cardiovascular Disorders, Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China临床科室心脏内科中心首都医科大学附属安贞医院[2]BGI Genomics, BGI-Shenzhen, Shenzhen, China[3]Beijing Advanced Innovation Center for Big Data and Brain Computing (BDBC), Beihang University, Beijing, China[4]James D. Watson Institute of Genome Sciences, Hangzhou, China[5]The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[6]SKLSDE Lab, Beihang University, Beijing, China[7]State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
Colorectal cancer is the fifth prevalent cancer in China. Nevertheless, a large-scale characterization of Chinese colorectal cancer mutation spectrum has not been carried out. In this study, we have performed whole exome-sequencing analysis of 98 patients' tumor samples with matched pairs of normal colon tissues using Illumina and Complete Genomics high-throughput sequencing platforms. Canonical CRC somatic gene mutations with high prevalence (>10%) have been verified, including TP53, APC, KRAS, SMAD4, FBXW7 and PIK3CA. PEG3 is identified as a novel frequently mutated gene (10.6%). APC and Wnt signaling exhibit significantly lower mutation frequencies than those in TCGA data. Analysis with clinical characteristics indicates that APC gene and Wnt signaling display lower mutation rate in lymph node positive cancer than negative ones, which are not observed in TCGA data. APC gene and Wnt signaling are considered as the key molecule and pathway for colorectal cancer initiation, and these findings greatly undermine their importance in tumor progression for Chinese patients. Taken together, the application of next-generation sequencing has led to the determination of novel somatic mutations and alternative disease mechanisms in colorectal cancer progression, which may be useful for understanding disease mechanism and personalizing treatment for Chinese patients.
基金:
This project is supported by National High-tech R&D Program (863 Program) [2012AA02A201], National Natural Science Foundation of China [81672818, U1636210 & 61421003], Guangzhou Science and Technology Program Key Projects [201604020005] and Beijing Advanced Innovation Center for Big Data and Brain Computing.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版:
无
第一作者:
第一作者机构:[1]Beijing Anzhen Hospital, Capital Medical University, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Collaborative Innovation Center for Cardiovascular Disorders, Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China[3]Beijing Advanced Innovation Center for Big Data and Brain Computing (BDBC), Beihang University, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]Beijing Anzhen Hospital, Capital Medical University, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Collaborative Innovation Center for Cardiovascular Disorders, Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, China[2]BGI Genomics, BGI-Shenzhen, Shenzhen, China[7]State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
推荐引用方式(GB/T 7714):
Zhe Liu,Chao Yang,Xiangchun Li,et al.The landscape of somatic mutation in sporadic Chinese colorectal cancer.[J].Oncotarget.2018,9(44):27412-27422.doi:10.18632/oncotarget.25287.
APA:
Zhe Liu,Chao Yang,Xiangchun Li,Wen Luo,Bhaskar Roy...&Jie Du.(2018).The landscape of somatic mutation in sporadic Chinese colorectal cancer..Oncotarget,9,(44)
MLA:
Zhe Liu,et al."The landscape of somatic mutation in sporadic Chinese colorectal cancer.".Oncotarget 9..44(2018):27412-27422